Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RV-NY-ESO TCR PBMC |
Trade Name | |
Synonyms | RV-NYESO TCR PBMC |
Drug Descriptions |
RV-NY-ESO TCR PBMC are peripheral blood mononuclear cells that have been engineered to express an NY-ESO-1-specific T-cell receptor, which may result in enhanced anti-tumor immunity (PMID: 25038231, PMID: 30409823). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C146939 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + Cyclophosphamide + Fludarabine + RV-NY-ESO TCR PBMC | Aldesleukin Cyclophosphamide Fludarabine RV-NY-ESO TCR PBMC | 0 | 0 |
Aldesleukin + LV-NY-ESO TCR/sr39TK PBSC + RV-NY-ESO TCR PBMC | Aldesleukin LV-NY-ESO TCR/sr39TK PBSC RV-NY-ESO TCR PBMC | 0 | 2 |
RV-NY-ESO TCR PBMC | RV-NY-ESO TCR PBMC | 0 | 0 |